When you have secondary progressive multiple sclerosis (SPMS), everyday tasks such as following conversations, recalling recent events, or managing different responsibilities can become more ...
The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...
At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness ...
eMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, ...
Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review ...
PTC Therapeutics is a commercial stage biotechnology firm. Its last Phase 2 trial, investigating PTC518 in Huntington's disease, released mixed results about the drug efficacy. We think a Phase 3 ...
The following is a summary of “Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy,” published in the April 2025 issue of Journal of Neurology by ...
Credit: Getty Images In an interim analysis of ENLIGHTEN, researchers described changes in cognitive function over 1 year in patients with MS. For the Symbol Digit Modalities Test, clinically ...
Please provide your email address to receive an email when new articles are posted on . Prolonged REM sleep latency was associated with three key Alzheimer’s-specific pathological changes. REM sleep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback